# AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma

> **NCT03434769** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Benjamin Tomlinson** · enrollment: 31 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** CAR-T Cells

## Key facts

- **NCT ID:** NCT03434769
- **Lead sponsor:** Benjamin Tomlinson
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-07-09
- **Primary completion:** 2023-03-01
- **Final completion:** 2036-02
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03434769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03434769, "AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03434769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*